| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 373.4 | 351.7 | 299.5 |
| Other income | 2.2 | 2.7 | 2.3 |
| Total income | 375.6 | 354.3 | 301.8 |
| Profit before exceptional items & tax | 40.1 | 24.3 | 27.1 |
| Profit before tax | 40.1 | 24.3 | 27.1 |
| Net profit | 26.5 | 15.1 | 20.9 |
| Operating margin | 10.7% | 6.9% | 9.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +26.80% |
|---|---|
| Net profit, quarter on quarter | +75.50% |
| Revenue, year on year | +24.70% |
| Operating profit, year on year | +52.80% |
| Operating profit, quarter on quarter | +75.50% |
NSE results filing, NSE: SMT. Figures extracted from the filing.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Sahajanand Medical Technologies Earnings Call Transcript: Key Takeaways
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Sahajanand Medical Technologies Acquisition Worth ₹7.33 Cr
Sahajanand Medical's Irish subsidiary approved up to USD 7,80,000 investment in SNP Medical Corp. This lifts its stake to 17.19%, a related-party deal at arm's length.
- Value
- ₹7.33 Cr
- Execution
- Tentatively completed by 31 March 2027
Sahajanand Medical Technologies Investor Presentation: Key Takeaways
Q2 FY27 record: revenue ₹3,734mn (+24.7%), EBITDA ₹656mn (17.6% margin), PAT ₹265mn (+26.6%). H1 revenue ₹7,251mn (+24.9%). Growth led by Other and Shockwave-type SH products.
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Sahajanand Medical Technologies Credit Rating
CRISIL has upgraded Sahajanand Medical Technologies' long-term bank facility rating to CRISIL A-/Stable from BBB+/Stable. The upgrade reflects improved business risk, growing scale, and sustained profitability across its global stent manufacturing operations.
- Value
- ₹300.0 Cr